Acrivon Therapeutics, Inc. Common Stock (ACRV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.28 Million) by net assets ($128.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acrivon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Acrivon Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Acrivon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acrivon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mr Bricolage
PA:ALMRB
|
0.019x |
|
VHM Ltd
AU:VHM
|
-0.041x |
|
Precipitate Gold Corp
V:PRG
|
-0.093x |
|
Assems Inc.
KQ:136410
|
0.064x |
|
Sam Jung Pulp
KO:009770
|
0.010x |
|
Power Metals Corp
V:PWM
|
-0.018x |
|
Dr. Hönle AG
F:HNL
|
0.038x |
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
-0.504x |
Annual Cash Flow Conversion Efficiency for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Acrivon Therapeutics, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $176.79 Million | $-65.67 Million | -0.371x | -5.58% |
| 2023-12-31 | $121.19 Million | $-42.64 Million | -0.352x | -99.16% |
| 2022-12-31 | $170.47 Million | $-30.12 Million | -0.177x | -130.08% |
| 2021-12-31 | $-23.81 Million | $-13.98 Million | 0.587x | +76.26% |
| 2020-12-31 | $-8.41 Million | $-2.80 Million | 0.333x | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more